Diagnosis - PCA3 Test

The Prostate Cancer gene 3 (PCA3) is a new gene-based test, which is performed collecting the first flow of the urine, after prostatic massage through the digital rectal examination , PCA3 is highly specific for prostate cancer, and unlike PSA, does not increase in the presence of conditions such as benign prostatic hypertrophy or prostatitis. Recent studies have shown that the PCA3 test will improve the diagnostic accuracy in the detection of prostate cancer, especially in cases in which other clinical investigations, such as the PSA test, provide questionable results.

PCA3 score is a useful tool to assess non-invasively the presence of prostate cancer. It has been observed a significant association between PCA3 and tumor volume as well as with the Gleason score of the prostatic biopsy. In addition, the PCA3 score was better in predicting the total tumor volume surpassing other known variables associated with tumor volume as the Trans-Rectal Ultrasound Prostate, Gleason score and PSA. PCA3 score could be used together with the current clinical tests to improve the diagnosis of prostate cancer and to evaluate the opportunity to perform a biopsy.